Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Protocol ID
CONNECT2108
Disease (Sub Disease)
Adamantinomatous Craniopharyngioma
Diagnosis Stage
Relapsed/refractory
Location
NSW, WA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Nationwide Children's Hospital
Collaborators
Children's Hospital Colorado
Trial Status
Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 25 Years
International registry ID's
NCT05286788
Back to Registry
Study Title Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Protocol ID CONNECT2108
Disease (Sub Disease) Adamantinomatous Craniopharyngioma
Diagnosis Stage Relapsed/refractory
Location NSW / WA
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ Nationwide Children's Hospital/
Collaborators Children's Hospital Colorado
Links https://clinicaltrials.gov/ct2/show/NCT05286788
Trial Status Open
Trial Open Date 08/05/2023
Sites Perth Children's Hospital / Sydney Children's Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility 1 Year to 25 Years
International registry ID's NCT05286788